RAPP
Rapport Therapeutics Inc

436
Loading...
Loading...
News
all
press releases
News Placeholder
RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal
Rapport Therapeutics stock jumps 62% in a week as mid-stage study of RAP-219 meets goals in drug-resistant epilepsy patients.
Zacks·6d ago
News Placeholder
Rapport Therapeutics Stock Rockets 204% Pre-Market To Head Toward All-Time Highs – Here’s What Happened
The company said that it now plans to advance the investigational therapy into two late-stage trials in the third quarter of 2026.
Stocktwits·10d ago

Latest RAPP News

View

Advertisement. Remove ads.

Advertisement. Remove ads.